Therefore, our results demonstrate that PP2A inhibition is a common event with a high clinical relevance in breast cancer and that the use of PP2A activators such as FTY720 has a potential therapeutic value and could represent an alternative therapeutic strategy for treating breast cancer patients. The gene discussed is PTPA; the disease is breast cancer.